STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRTX
  4. [Form 4] Vertex Pharmaceuticals Inc Insider Trading Activity

Vertex Form 4: Director sale under 10b5-1 plan reduces holding to 4,565

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals (VRTX), reported a sale of 266 shares of common stock on 08/27/2025 at a price of $386.69 per share, leaving her with 4,565 shares beneficially owned. The filing states the transaction was made pursuant to a company-approved Rule 10b5-1 trading plan entered on 05/27/2025. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The report discloses a single non-derivative sale and confirms the use of an affirmative-defense trading plan.

Positive

  • Transaction disclosed promptly via Form 4, supporting transparency
  • Sale executed under a company-approved Rule 10b5-1 trading plan, indicating pre-scheduled, compliant trading

Negative

  • Insider sale of 266 shares reduced direct beneficial ownership to 4,565 shares

Insights

TL;DR: Director sold a small number of shares under a 10b5-1 plan; transaction appears procedural, not a broad insider liquidation.

The sale of 266 shares at $386.69 reduced director-level ownership to 4,565 shares. The filing explicitly states the trade was executed under a Rule 10b5-1 plan established 05/27/2025, which provides an affirmative defense for scheduled trades. From a market-impact perspective, the transaction is small and routine; no derivatives, acquisitions, or material changes to ownership percentage are reported. This filing increases transparency about insider activity but does not by itself signal a change in company fundamentals.

TL;DR: Use of a board-approved 10b5-1 plan is governance-aligned and reduces concerns about opportunistic trading.

The report shows compliance with Section 16 reporting and indicates the director used a pre-established trading plan dated 05/27/2025. The Form 4 is executed via attorney-in-fact and properly discloses the sale date, price, and remaining holdings. This disclosure demonstrates procedural adherence to insider trading policies and timely public reporting, supporting governance transparency.

Insider Bhatia Sangeeta N.
Role Director
Sold 266 shs ($103K)
Type Security Shares Price Value
Sale Common Stock 266 $386.69 $103K
Holdings After Transaction: Common Stock — 4,565 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bhatia Sangeeta N.
(Last) (First) (Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
(Street)
BOSTON MA 02210
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 S(1) 266 D $386.69 4,565 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact 08/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Sangeeta N. Bhatia report on Form 4 for VRTX?

The Form 4 reports a sale of 266 shares of Vertex common stock on 08/27/2025 at $386.69 per share, leaving 4,565 shares beneficially owned.

Was the VRTX insider sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to a company-approved Rule 10b5-1 trading plan entered on 05/27/2025.

Who filed the Form 4 for the VRTX transaction and when was it signed?

The Form 4 was signed by an attorney-in-fact, Christiana Stevenson, on 08/29/2025.

How many VRTX shares does the reporting person own after the reported transaction?

After the sale, the reporting person beneficially owns 4,565 shares of Vertex common stock.

Did the Form 4 report any derivative transactions for VRTX?

No. The filing shows only a non-derivative sale of common stock and contains no reported derivative transactions.